Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Walmsley

Showing results (71-80 of 199) with videos related to

Pageof 20
Sort By:
Journal of Clinical Immunology|May 15, 2014
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccineKaren K Yam, Erica Gipson, Marina Klein, et al.
AIDS Patient Care and Stds|August 24, 2016
The Association Between HIV Disclosure Status and Perceived Barriers to Care Faced by Women Living with HIV in Latin America, China, Central/Eastern Europe, and Western Europe/CanadaMona Loutfy, Margaret Johnson, Sharon Walmsley, et al.
The New England Journal of Medicine|April 12, 2002
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitisDaniel F Martin, Juan Sierra-Madero, Sharon Walmsley, et al.
Plos One|May 4, 2017
A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infectionNasheed Moqueet, Cynthia Kanagaratham, M John Gill, et al.
AIDS (London, England)|November 24, 2025
Gut microbiome and healthy aging in HIV: data from the correlates of healthy aging in geriatric HIV (CHANGE HIV) cohortEric Armstrong, Eugene Seo, Bryan Boyachuk, et al.
HIV Clinical Trials|October 30, 2003
Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapyMona Loutfy, Janet Raboud, Courtney Thompson, et al.
Plos One|April 23, 2011
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adultsCurtis Cooper, Anona Thorne, Marina Klein, et al.
BMJ Open|September 24, 2017
Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccineCatia T Perciani, Walter Jaoko, Sharon Walmsley, et al.
The Journal of Infectious Diseases|December 16, 2003
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideSharon Walmsley, Keith Henry, Christine Katlama, et al.
Plos One|April 19, 2021
Estimating an individual-level deprivation index for HIV/HCV coinfected persons in CanadaAdam Palayew, Alexandra M Schmidt, Sahar Saeed, et al.
Pageof 20

Showing results (71-80 of 199) with videos related to

Sort By:
Pageof 20
Journal of Clinical Immunology|May 15, 2014
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccineKaren K Yam, Erica Gipson, Marina Klein, et al.
AIDS Patient Care and Stds|August 24, 2016
The Association Between HIV Disclosure Status and Perceived Barriers to Care Faced by Women Living with HIV in Latin America, China, Central/Eastern Europe, and Western Europe/CanadaMona Loutfy, Margaret Johnson, Sharon Walmsley, et al.
The New England Journal of Medicine|April 12, 2002
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitisDaniel F Martin, Juan Sierra-Madero, Sharon Walmsley, et al.
Plos One|May 4, 2017
A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infectionNasheed Moqueet, Cynthia Kanagaratham, M John Gill, et al.
AIDS (London, England)|November 24, 2025
Gut microbiome and healthy aging in HIV: data from the correlates of healthy aging in geriatric HIV (CHANGE HIV) cohortEric Armstrong, Eugene Seo, Bryan Boyachuk, et al.
HIV Clinical Trials|October 30, 2003
Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapyMona Loutfy, Janet Raboud, Courtney Thompson, et al.
Plos One|April 23, 2011
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adultsCurtis Cooper, Anona Thorne, Marina Klein, et al.
BMJ Open|September 24, 2017
Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccineCatia T Perciani, Walter Jaoko, Sharon Walmsley, et al.
The Journal of Infectious Diseases|December 16, 2003
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideSharon Walmsley, Keith Henry, Christine Katlama, et al.
Plos One|April 19, 2021
Estimating an individual-level deprivation index for HIV/HCV coinfected persons in CanadaAdam Palayew, Alexandra M Schmidt, Sahar Saeed, et al.
Pageof 20